Oncology News, Insights, Stories by OncoDaily

SOHO Spain 2025
2025-02-27 09:30 - 2025-02-28 19:30 (Europe/Madrid) | Madrid, Madrid, Spain
SOHO Spain 2025 will be held from February 27-28, 2025 at Madrid, Spain.
The SOHO Spain 2025 conference, organized by the Society of Hematologic Oncology (SOHO), is a global event dedicated to clinicians, research scientists, and healthcare professionals specializing in the research and treatment of hematologic malignancies. Established in 2012, SOHO’s mission is to accelerate research and education through the exchange of scientific information. With nearly 9,500 members from 110 countries, the society focuses on promoting research, education, clinical studies, and optimal patient care across various hematologic disorders.
The conference will feature general sessions on key topics such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphocytic Leukemia, among others. Notable directors for the event include Dr. Guillermo García-Manero from the University of Texas MD Anderson Cancer Center and Dr. Adolfo de la Fuente Burguera from MD Anderson Cancer Center Madrid – Hospiten, Spain. This event provides a platform for sharing cutting-edge research, advancing clinical practices, and fostering collaboration in the fight against hematologic malignancies.
The Registration opens on February 20th.

AACR IO Conference 2025
2025-02-23 15:30 - 2025-02-26 14:30 (America/Denver) | JW Marriott, 900 W Olympic Blvd, Los Angeles, CA, 90015, United States
The AACR IO 2025 will be held at the JW Marriott Los Angeles, on February 23-26. It is organized by the American Association for Cancer Research.
This conference will explore the latest in immunology, inflammation, and cancer immunotherapies, including IO drugs, vaccines, and cellular therapies.
With a program designed for everyone—from basic scientists to clinical investigators—attendees can expect keynote lectures, symposia, educational sessions, and poster presentations. Highlights include late-breaking clinical trial sessions showcasing new treatments and combinations that could change cancer care.
Don’t miss this opportunity to connect with experts and discover the cutting-edge advancements in the field. Register here.
Find more information about the AACR at OncoDaily.com.

The Highlights of ASH in Asia-Pacific
2025-02-22 08:00 - 2025-02-23 17:30 (Asia/Tokyo) | PACIFICO Yokohama, 1 Chome-1-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa, 220-0012, Japan
The Highlights of ASH in Asia-Pacific, taking place on February 22-23, 2025, at PACIFICO Yokohama in Japan, will offer a comprehensive overview of significant updates in clinical and translational hematologic research.
This two-day event will cover the most influential research presented at the latest American Society of Hematology (ASH) annual meeting, offering a unique opportunity for attendees to learn how the latest scientific discoveries can directly impact the study and practice of hematology. The event aims to bridge the gap between research advancements and their translation into cutting-edge patient care.
The program will be co-chaired by leading experts in the field, including Dr. Akifumi Takaori-Kondo and Dr. Kinuko Mitani from the Japanese Society of Hematology, along with Dr. Jonathan Kaufman and Dr. Jia Ruan from the American Society of Hematology. Attendees will gain valuable insights into both malignant and non-malignant hematology and engage in discussions with the world’s leading hematology professionals. This event presents a premier opportunity for learning and collaboration within the field.
Registration is open!

ESGO 2025
2025-02-20 00:00 - 2025-02-23 00:00 (Europe/Rome) | Rome Convention Center La Nuvola, Piazza J.F. Kennedy - 00144 Rome, Rome, Italy
The ESGO 26th European Gynaecological Oncology Congress, taking place from February 20-23, 2025, in Rome, Italy, promises to be an exceptional educational event for those involved in the field of gynaecological oncology. The congress will feature over 50 scientific sessions, highlighting the latest advancements in medical and scientific research, treatment approaches, and care strategies for gynaecological cancers. These sessions will be delivered by world-renowned experts, offering attendees an invaluable opportunity to stay at the forefront of the field.
Under the leadership of ESGO President Prof. Anna Fagotti and Congress Local Chair Prof. Isabelle Ray-Coquard, the event will present a comprehensive and inspiring programme aimed at advancing both knowledge and clinical practice. The congress is expected to foster collaboration, innovation, and a shared commitment to improving outcomes for patients with gynaecological cancers. Save the date for this significant gathering in Rome to engage with cutting-edge research and network with leaders in the field.
The Registration is Open until February 14th.

TRCCC 2025
2025-02-19 12:00 - 2025-02-21 13:30 (America/Halifax) | Seven Springs Mountain Resort, Champion, PA, 777 Water Wheel Dr, Champion, PA, Champion, 15622, United States
TRCCC 2025 will be held on February 19-21, 2025, at the Seven Springs Mountain Resort in Champion, PA.
This event will serve as a premier gathering for cancer researchers, clinicians, and industry professionals, fostering collaboration and innovation in the field of cancer research. The TRCCC Annual Meeting is a unique opportunity for attendees to engage in discussions around cutting-edge discoveries, emerging therapies, and the latest advancements in translational oncology.
The theme of this year’s meeting will focus on accelerating the translation of basic scientific discoveries into clinical applications. With a diverse range of presentations, panel discussions, and networking opportunities, the event will cover the latest research in areas such as immunotherapy, precision medicine, targeted therapies, and novel treatment approaches. The TRCCC Annual Meeting is designed to provide a collaborative environment for sharing ideas and forging new partnerships, helping to bridge the gap between laboratory discoveries and real-world clinical applications.
Abstract Submission Deadline is December 18th, 2024.
Registration Deadline is January 15, 2025.

Frontiers Symposium on Transformation in Cancer Care Delivery
2025-02-17 16:00 - 2025-02-19 16:00 (America/Halifax) | Salt Lake Marriott Downtown at City Creek, 75 South West Temple Street, Salt Lake City, Utah, 84101, United States
Frontiers Symposium on Transformation in Cancer Care Delivery will be held from February 17-19, 2025 at the Marriott Downtown City Creek in Salt Lake City, Utah.
This Symposium will convene leaders, innovators, and practitioners from across the oncology field. This premier event will spotlight emerging models in cancer care that address the entire patient continuum—from screening and risk assessment to diagnosis, treatment, and survivorship. With a focus on transformative approaches, the symposium will feature insightful presentations and dynamic discussions to advance frameworks aimed at improving cancer care and patient outcomes.
Participants will delve into essential areas such as early detection gaps, precise risk assessment, treatment innovations, and survivorship care. This event provides a collaborative platform for oncology professionals to explore and contribute to the next phase of cancer care, offering an invaluable opportunity for thought exchange among top minds in the field.

Second Global Oncothon
2025-02-15 | Rome Metropolitan City
OncoDaily, in partnership with the International Society of Pediatric Oncology (SIOP), is excited to announce the Second Global OncoThon, a 24-hour virtual event aimed at raising vital funds and awareness for pediatric cancer research. Set to take place on February 15, 2025, in honor of Childhood Cancer Awareness Day, this global telethon will bring together individuals and organizations from around the world to work toward a common goal: ensuring every child has the opportunity for a cancer-free future.
Childhood cancer remains one of the leading causes of death by disease in children aged 1 to 19. Unfortunately, there are significantly fewer drugs approved for pediatric cancer compared to over 200 approved for adults. Each year, nearly half a million children are diagnosed with cancer, and hundreds of thousands of lives are lost globally. Despite this, childhood cancer is still classified as a rare disease. The pharmaceutical industry and venture capitalists often show limited interest in supporting initiatives beyond academic research due to the smaller market size of pediatric cancer compared to adult cancers. Without industry leadership, the approval of new drugs for pediatric cancer becomes nearly impossible.
This event will be a day dedicated to connection, compassion, and action. It provides an opportunity for everyone to unite and declare that no child should ever have to face cancer alone. The Second Global OncoThon is our moment to inspire change and push for the breakthroughs that every child deserves.

ASCO Genitourinary Cancers Symposium 2025
2025-02-13 07:00 - 2025-02-15 15:30 (America/Denver) | Moscone West, 800 Howard Street, San Francisco, United States
The 2025 ASCO Genitourinary Cancers Symposium will take place from February 13-15 at Moscone West in San Francisco.
This event will showcase the latest research and best practices in GU cancer care, featuring expert talks and engaging discussions. Attendees can expect a comprehensive program that includes keynote presentations, panel discussions, and interactive sessions focused on advancements in diagnosis, treatment, and patient management for GU cancers.
This is an invaluable opportunity for healthcare professionals to engage with leading researchers, gain insights into emerging therapies, and enhance their clinical practice. The symposium is co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Urologic Oncology.
Register in-person or online for this opportunity to connect with leaders in the field and learn about cutting-edge treatments and strategies.
Find more information about ASCO at OncoDaily.com.

EHA-EBMT 7th European CAR T-cell Meeting
2025-02-06 00:00 - 2025-02-08 00:00 (Europe/Helsinki) | Palais de la Musique et des Congrès, Place de Bordeaux, Strasbourg, 67000, France
EHA-EBMT 7th European CAR T-cell Meeting will be held from 6 February 2025 – 8 February 2025, at Strasbourg, France.
The meeting will cover a broad range of topics in CAR T-cell therapy, including the latest unpublished clinical data, advancements in manufacturing, toxicity modeling, CAR design, and delivery methods. Participants will explore novel applications of CAR T-cell therapy and hear from leading experts in the field. It’s an excellent opportunity to stay updated on cutting-edge research and connect with peers and professionals driving innovation in CAR T-cell therapy.
For Registration Visit Here.

International Childhood Cancer Day 2025 by SIOP Europe
2025-02-04 16:00 - 18:00 (America/Halifax) | European Parliament, Brussels, Rue Wiertz 60, 1050 Ixelles, Brussels, Belgium
International Childhood Cancer Day 2025 by SIOP Europe will be held at February 4th, 2025 at European Parliament, Brussels.
The International Children Cancer Day 2025 conference focuses on the theme “Cross-Border Access to Care, Research, and Training: Reducing Inequalities for Children with Cancer.” Building on the insights gathered from the previous year, the second phase of the campaign aims to shift towards actionable solutions to address the challenges faced by children with cancer worldwide.
The conference will delve into collaborative efforts and initiatives emerging from different regions to improve access to care, research, and training for pediatric cancer. Key discussions will highlight innovative measures and successful models aimed at overcoming barriers such as limited healthcare infrastructure, lack of access to treatment, and disparities in medical training.
This year’s focus is on fostering global collaboration and knowledge exchange, creating a platform where experts, healthcare providers, researchers, and advocacy groups can share best practices, policy recommendations, and innovative solutions that have been implemented across various regions to tackle inequities in cancer care for children. The aim is to work collectively to reduce inequalities and ensure that every child has access to the best possible care, research, and training opportunities, regardless of geographical location.

World Cancer Day
2025-02-04 | WorldWide
World Cancer Day is observed annually on February 4 to raise awareness about cancer, promote its prevention, and inspire global action to tackle the growing cancer crisis. The day is coordinated by the Union for International Cancer Control (UICC).
The Origins of World Cancer Day

World Cancer Day was established on 4 February 2000 during the World Summit Against Cancer for the New Millennium in Paris. The Paris Charter, which emerged from this summit, was designed to promote cancer research, prevention, patient services, and awareness. It also aimed to rally global efforts to make progress in the fight against cancer. As part of the Charter’s initiatives, World Cancer Day was adopted as a means to unite the global community in addressing the challenges posed by cancer.

What do we know about World Cancer Day?
UICC organizes World Cancer Day campaigns in three-year cycles, allowing for a deeper exploration of each year’s theme to maximize its impact and drive meaningful change. The new theme for World Cancer Day 2025-2027, “United by Unique,” focuses on putting people at the center of cancer care and highlighting their individual stories in the conversation.
Through individual, collective, and governmental efforts, World Cancer Day envisions a world where millions of cancer-related deaths are prevented, and life-saving treatments are accessible to all, regardless of who they are or where they live. Every year, numerous activities and events take place across the globe, bringing communities, organizations, and individuals together in various settings—from schools to hospitals, businesses, parks, and places of worship, both offline and online. These events serve as a powerful reminder that everyone has a part to play in reducing the global burden of cancer.

9th Annual ELLOK Conference
2025-02-03 09:00 - 2025-02-05 15:00 (Europe/Athens) | Wyndham Grand Athens Hotel, Meg. Alexandrou 2, Athina, Athens, 10437, Greece
The 9th Annual ELLOK Conference will take place from February 3rd to 5th, 2025, at the Wyndham Grand Athens Hotel.
The event is organized by Hellenic Cancer Federation (ELLOK) and the theme of this year’s conference is “From Planning to Implementation”. This annual event is strategically aligned with World Cancer Day on February 4th, providing a platform to address critical health policy issues and explore developments that impact the quality of oncology care and services. The conference will bring together a wide range of stakeholders, including policymakers, healthcare professionals, patient organizations, and industry representatives, to engage in discussions that will shape the future of cancer care both in Greece and globally.
The 9th ELLOK Conference will serve as the launch event for the Union for International Cancer Control (UICC)’s three-year global campaign, “United by Unique” (2025–2027). This campaign emphasizes the importance of collective efforts in cancer control while also celebrating the individuality of patient experiences and contributions to advocacy.
The purpose of the conference is to address critical concerns in oncology care, such as improving patient access to innovative treatments, advancing policy, and promoting multidisciplinary approaches to care. Experts from various fields – including policymakers, academia, the scientific community, healthcare professionals, industry leaders, and patient organizations – will gather to exchange insights and collaborate on developing effective strategies. With a focus on both theoretical frameworks and practical applications, the conference aims to drive meaningful change in oncology care at both the national and European levels.
Registration is open for the event.

AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
2025-02-01 00:00 - 2025-02-04 00:00 (America/Halifax) | The Westin San Diego Gaslamp Quarter, 910 Broadway Cir, San Diego, CA, San Diego, CA, 92101, United States
AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer will be held from February 1-4, 2025.
The upcoming AACR Special Conference, chaired by Stephen Baylin, Margaret Goodell, and Peter Jones will focus on the pivotal role of DNA methylation in human cancer, celebrating the 25th Anniversary of the groundbreaking 1999 AACR Special Conference on “DNA Methylation, Imprinting, and the Epigenetics of Cancer.” This conference aims to spotlight recent research advances in the field of DNA methylation, which has emerged as a central mechanism in cancer biology. It will emphasize the significance of DNA methylation specifically, rather than covering broader chromatin biology topics like histone modifications.
The conference will provide extensive opportunities for presentation, particularly for highly-rated abstracts, with podium presentations, plenary sessions, and “lightning” talks scheduled before each poster session. Researchers, clinicians, and scientists will gather in San Diego for this exciting event, which promises to offer valuable insights into the molecular underpinnings of cancer and the therapeutic potential of DNA methylation-based approaches.
Advance Registration Deadline is December 20th.

13th AACR-JCA Joint Conference
2025-02-01 00:00 - 2025-02-03 00:00 (America/Halifax) | Hyatt Regency Maui, 200 Nohea Kai Dr, Lahaina, HI, Maui, Hawaii, 96761, United States
13th AACR-JCA Joint Conference will be held from February 1-3, 2025 at Maui, Hawaii.
The 13th AACR-JCA Joint Conference is a significant event hosted by the American Association for Cancer Research (AACR) in collaboration with the Japanese Cancer Association (JCA). This conference has a longstanding tradition of bringing together top cancer researchers from the United States, Japan, and around the world to share groundbreaking findings and discuss the latest advancements in basic, translational, and clinical cancer research.
The event aims to foster both formal and informal interactions among scientists and healthcare professionals, promoting international collaborations in the field of cancer research. It provides a unique platform for investigators at all career stages to engage with the most current research developments, share ideas, and collaborate on new approaches to cancer treatment and prevention.
Just like its previous editions, the conference will present a comprehensive overview of contemporary cancer research, addressing critical issues across various disciplines. Participants can expect to explore cutting-edge topics, exchange knowledge, and expand their networks, contributing to the advancement of cancer research globally.
Registration is Open until December 20, 2024.

Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond by SPCC
2025-01-29 18:00 - 21:00 (America/Halifax) | Rome Metropolitan City
Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond by SPCC will be held at January 29th, 2025 at 6 pm.

The Outlook for the HR+/HER2- MBC Treatment Landscape in 2025 and Beyond Live Webinar will focus on the latest advancements and future directions in treating HR+ HER2- metastatic breast cancer (MBC). Experts will review recent clinical trial data, discuss the current treatment landscape, and explore the role of novel therapies, including CDK4/6 inhibitors, PI3K inhibitors, and targeted therapies. The evolving landscape will also include next-generation treatments that could reshape patient care in the coming years.
Biomarker testing plays a central role in guiding treatment decisions for HR+ HER2- MBC, and the conference will cover how genomic tests and liquid biopsies, such as ctDNA, can help personalize therapies. A discussion will also take place on the balance between biomarker-driven therapies versus non-biomarker approaches, addressing when and how each strategy should be utilized in clinical practice.
The conference will also focus on optimizing treatment sequencing based on clinical characteristics such as tumor burden, mutational status, and patient performance. Esteemed speakers include Dr. Martin Miguel (Hospital General Universitario Gregorio Marañón, Spain), Dr. Neven Patrick (Universitaire Ziekenhuizen Leuven, Belgium), and Dr. Joyce O’Shaughnessy (Baylor-Sammons Cancer Center, USA), who will share their expertise on the latest research and treatment strategies for HR+ HER2- MBC.

AACR Conference on Translating Targeted Therapies in Combination with Radiotherapy
2025-01-26 18:00 - 2025-01-29 13:00 (America/Denver) | Hilton San Diego Bayfront, 1 Park Blvd, San Diego, CA, 92101, United States
The AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy, will be taking place at the Hilton San Diego Bayfront, on January 26-29, 2025. This conference will explore the future of radiation therapy, focusing on innovative areas like heavy ion therapy, FLASH radiation, and the synergy between radiation and targeted therapies.
This event is organized by the American Association for Cancer Research. It’s an exciting opportunity to learn how these advancements can personalize cancer treatment and improve long-term outcomes for patients.
Don’t miss your chance to be part of this transformative event in San Diego!

The Breathe for Hope Conference
2025-01-24 08:00 - 2025-01-25 20:30 (Africa/Cairo) | the Hilton Heliopolis Hotel in Cairo, Egypt, El-Orouba, Sheraton Al Matar, El Nozha, Cairo Governorate, El Nozha, Cairo, Al, Egypt
The Breathe for Hope Conference is a pioneering event that combines the expertise of the Oncothoracic International Cancer Association (OnTIC) and the Onco-Bronchology International Conference (OncoBroncho). Scheduled to take place on 24-25 January 2025 at the prestigious Hilton Cairo Heliopolis, this conference is designed to bring together leading professionals, researchers, and clinicians from across the globe to explore the latest advancements in oncology and lung health. The event will serve as a platform to share cutting-edge research, discuss innovative treatment strategies, and collaborate on future directions in the fight against lung cancer and other thoracic diseases.
Attendees can expect to engage in thought-provoking discussions, attend workshops, and hear from experts on various topics, from the latest molecular treatments to groundbreaking techniques in bronchoscopy and thoracic surgery. This conference represents an exciting opportunity to be at the forefront of cancer research and treatment, as experts come together to push the boundaries of what’s possible in improving patient outcomes.
Registeration is Open for the Event.

HEAL webinar series on the health impacts of per- and polyfluoroalkyl substances
2025-01-23 15:00 - 17:00 (America/Halifax) | Rome Metropolitan City
HEAL webinar series on the health impacts of per- and polyfluoroalkyl substances will be held on 23 January 2024 at 15:00 CET.
The HEAL Virtual Webinar Series on PFAS and Human Health is a crucial initiative aimed at raising awareness about the health impacts of PFAS (Per- and Polyfluoroalkyl Substances). These chemicals, widely used in consumer products, have been linked to various health concerns, including immune system disruption, cancer, and developmental issues. The series invites leading experts to discuss the health effects of PFAS exposure, with each webinar focusing on different aspects of this growing issue. The series aims to inform the public and policymakers on the importance of addressing PFAS contamination and its long-term health implications.
Organized in partnership with the Association of European Cancer Leagues (ECL), this session will explore the links between PFAS and cancer, considering the evaluation from the International Agency for Research on Cancer (IARC) and supporting epidemiological studies. The webinar will feature Dr. Tony Fletcher, an Associate Professor at the London School of Hygiene and Tropical Medicine, who has led research on PFAS exposure in communities in Ronneby, Sweden, and Veneto, Italy. His research has contributed to understanding the carcinogenic potential of PFAS and its widespread health risks.
This webinar is part of a broader effort to educate and raise awareness about the dangers of PFAS exposure. Recordings of previous webinars, including topics on the immune system and the effects of early-life exposure to PFAS, will also be made available for those who wish to catch up on the ongoing discussion. The series serves as a critical platform for sharing the latest scientific findings and fostering discussions on how to mitigate the health risks associated with these harmful substances.
Registration is Open.

ASCO Gastrointestinal Cancers Symposium 2025
2025-01-23 07:30 - 2025-01-25 16:00 (America/Denver) | Moscone West, 800 Howard Street, San Francisco, United States
The ASCO Gastrointestinal Cancers 2025 Symposium, happening on January 23-25 in Moscone West, San Francisco, will bring together top experts in gastrointestinal oncology. Attendees can look forward to insightful keynote talks, engaging panel discussions, and the latest research on treatments and diagnostics for gastrointestinal cancers.
The event will also showcase poster presentations from emerging researchers, offering great networking opportunities for everyone involved.
The Co-Organizers of the symposium are the American Society of Clinical Oncology, the American Gastroenterological Association, the American Society for Radiation Oncology and the Society of Surgical Oncology.
This symposium is a must-attend for anyone interested in the latest trends and innovations in the field, as it will play a vital role in shaping the future of patient care in gastrointestinal oncology.
Register here.

The 17th BGICC 2025
2025-01-23 00:00 - 2025-01-24 00:00 (Africa/Cairo) | the Hilton Heliopolis Hotel in Cairo, Egypt, El-Orouba, Sheraton Al Matar, El Nozha, Cairo Governorate, El Nozha, Cairo, Al, Egypt
The 17th BGICC 2025 (Breast, Gynecological and Immuno-oncology International Cancer Conference) is a premier event in the field of oncology, widely recognized as the largest and most prestigious cancer conference in both Africa and the Middle East. Scheduled to take place from January 23-24, 2025, at the Hilton Heliopolis Hotel in Cairo, Egypt, this conference serves as a hub for oncology professionals, researchers, and clinicians to gather and share cutting-edge knowledge and advancements in cancer care and treatment.
The conference will feature a comprehensive agenda that includes high-level lectures, interactive workshops, and specialized courses, providing participants with an opportunity to delve into the latest research and clinical practices in breast cancer, gynecological oncology, and immuno-oncology. The event aims to bridge the gap between scientific discovery and clinical application, offering insights into innovative therapies, emerging treatment protocols, and the evolving landscape of cancer care.
The 17th BGICC 2025 is set to be led by some of the most esteemed experts in oncology. The course will be directed by Prof. Manal El Mahdy from Ain Shams University, with Prof. Rouba Ali-Fehmi from the University of Michigan serving as the course co-director. These renowned experts will guide participants through discussions and sessions on the latest breakthroughs in cancer research and treatment.
By attending BGICC 2025, participants will not only gain valuable knowledge but also network with leaders in the oncology field, share ideas, and collaborate on global efforts to advance cancer treatment and patient care. The conference promises to be an exciting and impactful event that will shape the future of oncology in the region and beyond.
The Abstract Submission Closes at December 29th.
For Registration, visit here.

International BPDCN Day
2025-01-23 | WorldWide
January 23rd of 2025 marks the International BPDCN Day. We unite to shed light on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often remains underdiagnosed due to its rarity and complex presentation.
What do we know about BPDCN?
In 2008, BPDCN was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. BPDCN predominantly affects the skin, bone marrow, and lymph nodes, posing significant diagnostic and therapeutic challenges. Despite advances in hematology, much remains to be understood about its pathogenesis, optimal treatment strategies, and long-term outcomes. Greater awareness and focused research are critical to improving the prognosis for patients worldwide.
At present, there is no consensus on the optimal treatment of BPDCN. The majority of patients receive multi-agent chemotherapy with AML or ALL treatment regimens, while a few patients undergo allogeneic hematopoietic stem cell transplantation (HSCT). Different novel and innovative therapies are in development to target surface molecules in BPDCN. However, patients are still in need of better treatments and the optimal therapy for the disease remains to be determined.
What can we do for patients diagnosed with BPDCN?
Unfortunately, projects devoted to this mission are not many either. The BPDCN International Registry is one of them, aimed in building a large database of patients to investigate the characteristics and outcomes of the disease with different treatment regimens, evaluate prognostic factors, and generate data-based prospective treatment recommendations.
Let’s unite on International BPDCN Day to amplify our collective efforts, inspire new collaborations, and give hope to patients and their families. Together, we can make a meaningful difference in the fight against this disease.

Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR
2025-01-21 13:00 - 14:30 (America/Halifax) | Rome Metropolitan City
Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR will be held on January 21, 2025, Virtually.
The forum will explore the new generation of patient-centric cancer clinical trials, focusing on how advancements in cancer research will reshape the clinical trial process. As more people are expected to survive and live beyond cancer, largely due to clinical trials, the conference will highlight the ongoing transformation in trial design. The emphasis will be on creating more efficient, inclusive, and patient-focused trials that prioritize patient needs and preferences. This shift will be critical in ensuring broader access to innovative treatments and improving overall patient outcomes.
The upcoming session will feature a group of esteemed experts in the field of cancer research. Jan Tomlinson from the University of California, San Francisco, will share insights from a patient advocate’s perspective on the clinical trial experience. Patricia M. LoRusso, DO, PhD (HC), FAACR, from Yale Cancer Center, will discuss innovative clinical trial designs aimed at improving efficiency and inclusivity. David A. Tuveson, MD, PhD, FAACR, from CSHL Cancer Center, will highlight the Cancer Therapeutics Initiative, which focuses on translating basic research into clinical applications. Laura van ‘t Veer, PhD, from the University of California, San Francisco, will present on the second-generation design of the I-SPY 2 trial, driving advancements in precision medicine. These experts will cover a broad range of topics, all geared toward advancing cancer clinical trials and patient care.
Register Now!

2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents
2025-01-15 14:00 - 16:00 (Asia/Hong_Kong)
The Cancer Summit, organized by the China Anti-Cancer Association (CACA), OncoDaily, Sharing Progress in Cancer Care (SPCC), and the World Association for Integrative Oncology (WAIO), will take place on January 15, 2025 via Zoom and will feature simultaneous translation in English and Chinese.
The summit will be held at the following times:

China Standard Time: 02:00-04:00pm
US EST: 01:00-03:00am
Central European Time: 07:00-09:00am

The event highlights the crucial rule of collaboration in tackling the current challenges faced in oncology.
Read more about the event here.

Eastern Europe and Baltic Course I: Immunotherapy in Lung Cancer by IASLC
2024-12-30 10:00 - 12:00 (America/Halifax) | Rome Metropolitan City
Eastern Europe and Baltic Course I: Immunotherapy in Lung Cancer by IASLC will be held at December 30, 2024.

This Exclusive Virtual Course focuses on the latest updates in lung cancer treatment in Eastern Europe and the Balkan States, with a particular emphasis on immunotherapy. In Series I, leading thoracic oncology experts from the region will discuss how immunotherapy is revolutionizing lung cancer care. Key topics include the integration of biomarkers for immunotherapy, effective management strategies for advanced disease, and addressing challenges such as pneumonitis. Participants will gain valuable insights into the evolving landscape of lung cancer treatment, particularly in Eastern Europe and the Balkans, and learn how immunotherapy is improving patient outcomes in these regions.
See the Speakers of the Course Below:

Breast cancer highlights from the San Antonio Breast Cancer Symposium 2024 by SPCC
2024-12-19 18:00 - 19:00 (America/Halifax) | Rome Metropolitan City
Breast cancer highlights from the San Antonio Breast Cancer Symposium 2024 by SPCC will be held at December 19, 2024.
This live webinar will start with an introduction by Nadia Harbeck from Germany, setting the stage for the evening’s discussions. Shani Paluch-Shimon from Israel will then present the latest updates on Early Breast Cancer (EBC) from the 2024 San Antonio Breast Cancer Symposium, covering key advancements and findings. Following this, Fatima Cardoso from Portugal will provide insights into the updates on Advanced Breast Cancer (ABC) presented at the same symposium, highlighting new developments and treatments in this area.
After the presentations, there will be a 20-minute discussion and Q&A session where participants can engage with the speakers and ask questions. The event will conclude with closing remarks from Nadia Harbeck, summarizing the key points and takeaways from the session.
For more information about the 2024 San Antonio Breast Cancer Symposium, visit here.

LATAM Course II: Immunotherapy in Lung Cancer by IASLC
2024-12-19 16:00 - 17:00 (America/Halifax) | Rome Metropolitan City
LATAM Course II: Immunotherapy in Lung Cancer by IASLC will be held at December 19th, 2024.
The exclusive course on the latest updates in lung cancer treatment in LATAM, with a special focus on immunotherapy, will take place in Series II. Renowned thoracic oncology experts from the region will explore the role of immunotherapy in revolutionizing lung cancer care. The discussions will cover crucial topics, including the integration of biomarkers for immunotherapy, optimal management strategies for advanced disease, and addressing challenges like pneumonitis. Participants will have the opportunity to explore how immunotherapy will transform the landscape of lung cancer treatment in LATAM, offering hope for improved patient outcomes.
See the Speakers and Series II LATAM Team Below:

LATAM Course II: Immunotherapy in Lung Cancer by IASLC
2024-12-19 16:00 - 17:00 (America/Halifax) | Rome Metropolitan City
LATAM Course II: Immunotherapy in Lung Cancer by IASLC will be held at December 19, 2024.
This exclusive Live Course on the latest updates in lung cancer treatment, specifically focusing on immunotherapy, offers a deep dive into the transformative impact of immunotherapy on lung cancer care in Latin America (LATAM). In Series II of the course, leading thoracic oncology experts from the region will lead discussions on pivotal aspects of immunotherapy in lung cancer treatment.
Key topics will include the integration of biomarkers for immunotherapy, which play a critical role in selecting the right patients and optimizing treatment efficacy. Experts will also explore best management strategies for advanced lung cancer, addressing the evolving landscape of treatment options, and discuss specific challenges faced in clinical practice, such as the management of pneumonitis, a common side effect associated with immunotherapy.
The Link for Registration.
See the Speakers and Series II LATAM Team Below:

Haemato-oncology highlights from 66th ASH Annual Meeting by SPCC
2024-12-18 18:00 - 19:00 (America/Halifax) | Rome Metropolitan City
Haemato-oncology highlights from 66th ASH Annual Meeting by SPCC will be held at December 18, 2024.
This live webinar serves as a crucial platform for oncologists to stay informed about the latest research and breakthroughs in haemato-oncology, with key highlights from the ASH meeting. By providing insights into recent advancements, the webinar aims to deepen participants’ understanding, enhance their education, and promote best practices in haematology, ultimately contributing to improved patient care in the field.
The webinar will begin with an introduction by Jakob Passweg from Switzerland. David Gomez-Almaguer from Mexico will then present the latest highlights in stem cell transplantation and leukemia. Following that, Phillip Scheinberg from Brazil will provide key updates on bone marrow failure. After the presentations, there will be a discussion and Q&A session. The event will conclude with closing remarks by Jakob Passweg.
For more information about, the 66th ASH Annual Meeting visit here.
See the Speakers of this event below:

Jakob Passweg

David Gomez-Almaguer

Phillip Scheinberg

Immunotherapy and GI cancer. Learnings from the ESMO Congress 2024, ESMO Immuno-Oncology Congress 2024 and Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 by SPCC
2024-12-17 18:00 - 19:00 (America/Halifax) | Rome Metropolitan City
Immunotherapy and GI cancer. Learnings from the ESMO Congress 2024, ESMO Immuno-Oncology Congress 2024 and Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 by SPCC will be held at December 17th, 2024.
Join this Live Webinar on advancements in gastrointestinal (GI) cancer care, featuring experts Van Cutsem Eric, Neuzillet Cindy, and Ruiz-Garcia Erika. The event will explore recent breakthroughs in minimally invasive surgery, targeted therapies, and immunotherapy, which are improving survival rates. The speakers will discuss how molecular insights are driving personalized treatment and transforming patient outcomes. Don’t miss this opportunity to learn about the latest developments and future directions in GI cancer care.
The webinar will begin with an introduction by Eric Van Cutsem (BE), setting the stage for the discussions on the latest advancements in immuno-oncology for gastrointestinal cancers. Cindy Neuzillet (FR) will then present on the progress of immuno-oncology in biliary and pancreatic cancers, highlighting the most recent breakthroughs and clinical developments in these challenging and often difficult-to-treat cancers. Following this, Erika Ruiz Garcia (MX) will focus on the advances in immuno-oncology for colorectal and stomach cancer, exploring how emerging therapies are improving outcomes for patients with these common malignancies.
After the presentations, there will be an open discussion and Q&A session, where attendees can engage directly with the speakers, ask questions, and share insights. The webinar will conclude with closing remarks from Eric Van Cutsem (BE), summarizing the key points discussed and providing a forward-looking perspective on the future of immuno-oncology in GI cancer care. This session promises to be an informative and interactive opportunity for healthcare professionals and researchers to learn about the latest advancements in this rapidly evolving field.
Link to register and access the session.

SE Asia Course II: Immunotherapy in Lung Cancer By IASLC
2024-12-16 19:00 - 21:00 (Asia/Shanghai) | Rome Metropolitan City
SE Asia Course II: Immunotherapy in Lung Cancer By IASLC will be held on December 16th, 2024.
This exclusive course will offer the latest updates on lung cancer treatment in Southeast Asia, with a special focus on immunotherapy. In Series II, renowned thoracic oncology experts from the region will delve into the role of immunotherapy in revolutionizing lung cancer care. Discussions will cover crucial topics such as the integration of biomarkers for immunotherapy, the best management strategies for advanced disease, and addressing challenges like pneumonitis. Participants will have the opportunity to explore how immunotherapy is set to transform the landscape of lung cancer treatment in Southeast Asia, bringing hope for improved patient outcomes.
See the Speakers and Southeast Asia Team Below:
